CD4 and neoplasm: For patients in the ESCC cohort, the univariate analysis showed that tumor differentiation (poor vs. good), stage (local regional vs. distant metastasis), metastatic sites (none vs. one vs. ≥two sites), ECOG (0–1 vs. 2–4), eosinophil count (<0.115 vs. ≥0.115; <0.125 vs. ≥0.125), basophil count (<0.035 vs. ≥0.035; determined as median value), prealbumin level (normal vs. decreased<200), B-cell count (compared by quartile: <70 vs. 71–99 vs. 100–162 vs. >162), memory CD4+T cell count (<282 vs. ≥282), and ELR (<0.075 vs. ≥0.075) were associated with PFS (Table 2, Figure 4A).